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ABSTRACT
Hepatocellular carcinoma (HCC) is a cancer with a high mortality rate due to the 
fact that the diagnosis usually occurs at anadvanced stage. Even in case of curative 
surgical treatment, recurrence is common. Sorafenib and regorafenib are the only 
therapeutic agents that have been demonstrated to be effective in advanced HCC, 
thus novel curative approaches are urgently needed. Recent studies focus on the role 
of immune system in HCC. In fact, the unique immune response in the liver favors 
tolerance, which can represent a real challenge for conventional immunotherapy 
in these patients. Spontaneous immune responses against tumor antigens have 
been detected, and new immune therapies are under investigation: dendritic cell 
vaccination, immune-modulator strategy, and immune checkpoint inhibition. In recent 
years different clinical trials examining the use of immunotherapy to treat HCC have 
been conducted with initial promising results. This review article will summarize 
the literature data concerning the potential immunotherapeutic approaches in HCC 
patients.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of most 
frequently diagnosed malignances and the third cause 
of cancer-related deaths worldwide, with about 600,000 
death/years [1]. About 80%-90% of HCC developed into 
cirrhotic liver disease due to chronic viral hepatitis B 
or C [2]. Although surgery plays a fundamental role in 
the early stages, most of HCC patients diagnosed at an 
advanced stage of the disease or with hepatic impairment 
are treated with loco-regional or systemic therapies. 
Recurrence is observed in most of them within 5 years 
[3]. Only sorafenib and regorafenib, two oral multi-kinase 
inhibitors, have shown efficacy in advanced stages of this 
disease , providing a short increase of median overall 
survival (mOS) [4-6].
      Review
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Gastrointestinal cancer immunotherapy has had 
significant progress in the last few years [7]. In particular, 
recent studies focus on the role of immune system in 
HCC. The unique immune response in the liver favors 
tolerance, which could represent a genuine challenge for 
conventional therapies in HCC patients [8].
FROM LIVER IMMUNE SYSTEM 
TO HCC IMMUNE DISORDERS AND 
IMMUNOTHERAPEUTIC STRATEGY
The liver is an organ with a specific blood supply. 
Approximately 25% and 75% of the blood enters the liver 
through the hepatic artery and the portal vein, respectively. 
The latter drains into smaller diameter structures called 
sinusoids. Vascular resistance is very low in these 
structures, and the portal venous blood, which is loaded 
with nutrients and many microbial antigens from the 
intestine, flows extremely slowly into the sinusoids. In this 
phase, antigens are in contact with a great number of non-
parenchymal cells including liver sinusoidal endothelial 
cells (LSECs), hepatic stellate cells (h-SCs), Kupffer cells, 
dendritic cells (DCs), and lymphocytes. All these actors 
are potential protagonists in immune response. 
Under physiological conditions, different digestion 
metabolites and bacteria coming from the bowel to the 
liver passing through the portal system represent an 
antigenic hyperstimulation. To overcome autoimmune 
mechanisms, the liver develops a series of mechanisms 
aiming at self-tolerance: i) decrease of costimulatory 
immune receptors such as B7-1, B7-2; ii) up-regulation 
of programmed cell death protein 1 (PD-1) receptor and 
cytotoxic T-limphocite antigen-4 (CTLA4) immuno-
checkpoint inibitors on hepatic antigen presenting cells 
(h-APC) such as h-SCs , LSECs , and Kupffer cells 
[9,10]; iii) secretion of cytokines with interleukin (IL)-10 
and transforming growth factor β (TGF-β) most studied 
[11,12]. Similarly, hepatitis B virus or hepatitis C virus 
(HCV) infection, autoimmune hepatitis, alcohol abuse, 
non-alcoholic steatohepatitis lead to frequent chronic 
inflammatory liver insult resulting in a deregulation of 
T cell activities [13] with an increase of the expression 
of immune checkpoint inhibitors on h-APCs [14]. 
Moreover, tumor growth is favored by these mechanisms, 
which result amplified in HCC patients [15]. Cancer 
associated fibroblasts, essential components of the 
HCC microenviroment, inhibit natural killer (NK) cell 
function by releasing the immunosuppressive molecules 
prostaglandin E2 and indoleamine 2,3 dioxygenase (IDO) 
[16]. Moreover, several data support a possible correlation 
between the phenotype of infiltrating lymphocytes and 
the risk of relapse after transplantation or loco-regional 
treatments [17]. With regard to this, the expression of 
T-helper1 cytokines such as IL-1α, IL-1β, IL-2, and 
interferon (IFN)-γ in tumor tissue is associated with 
good prognosis, whereas T-helper2 cytokines such as IL-
4, IL-5, and IL-10 are upregulated in aggressive disease 
[8]. As well as in other solid tumors, forkhead box P3 
(FOXP3) + T-regs, a subset of CD4+ T cells specialized 
in the suppression of the host immune system against 
self antigens, promotes tumor development inducing a 
state of severe immune-suppression in HCC [18]. The 
suppressive function of FOXP3+ T-regs may be related to 
different mechanisms such as target cells killing by T-regs, 
modulation of target cell signaling via cell-cell contact, 
and secretion of immunosuppressive cytokines such as 
IL-10, IL-35, and TGF-β. The epigenetic regulation is 
patho-physiologically relevant for T-regs function and 
development . Furthermore, epigenetic mechanisms 
responsible for regulating the foxp3 gene expression have 
a key role in T-regs suppressive activity [19,20]. Moreover, 
an increased number of CD4+CD25+FOXP3+ Treg may 
reduce the activity of CD8+ T cells, promoting disease 
progression, with high mortality and reduced survival of 
these patients [21]. Subsequently, programmed cell death 
protein-ligand (PD-L) expression and FOXP3+ T-reg cell 
expression have been analyzed on tissue of 240 resected 
HCC patients, with a cross validation in an independent 
cohort of 125 HCC samples. Patients with a higher PD-L1 
tumor expression had a significantly poorer prognosis than 
patients with lower expression. The multivariate analysis 
demonstrated that PD-L1 expression was an independent 
predictor of recurrence after surgery. The prognostic value 
of PD-L1 expression was validated in the independent 
data set. PD-Ls expression significantly correlated with 
FOXP3+ lymphocyte infiltration. Moreover, tumor-
infiltrating PD1+CD8+ cytotoxic cells and T-reg cells were 
also independent prognostic factorsfor overall survival 
(OS) and post operative recurrence. [22]. However, it 
should be considered that, until today, the biological 
bases of pathogenesis/progression of HCC remain poorly 
defined. Figure 1 describes the principal pathogenetic 
mechanisms of immune-tolerance involved in HCC.
INTERACTION BETWEEN ANTI-
VEGF THERAPY AND HCC 
IMMUNOSURVEILLANCE
Vascular endothelial growth factor (VEGF)/
VEGF receptor (VEGFR) axis, one of the most 
important molecular pathways controlling angiogenesis, 
plays a key role in tumor microenviroment including 
immunosupression. VEGF is known to inhibit DCs 
maturation through the activation of NF-KB which is 
able to influence the differentiation of monocytes into 
DCs. In addition, VEGF promotes an immunosuppressive 
phenotype both increasing the DCs production of IDO, a 
strong inhibitor of T-cell activation, as well as inactivating 
STAT3 [23]. Interestingly, Motz et al. reported that VEGF 
could induce Fas Ligand expression in tumor endothelial 
cells, inhibiting cytotoxic T-lymphocyte (CTL) infiltration 
in the tumor and reducing their cytotoxic activity [24].
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Voron et al., on the other hand, showed that VEGF induces 
exhaustion in intratumoral CD8+ T cells by promoting the 
expression of PD-1 and other checkpoint molecules such 
us CTLA-4 and TIM-3 [25]. Myeloid-derived suppressor 
cells (MDSCs) were shown to inhibit NK cell activation 
though TGF-β and NK protein 30 and to regulate T-cell 
proliferation by L-arginine. Intratumoral MDSCs 
infiltration correlates with circulating VEGF levels in 
several solid tumors, including HCC [26]. Furthermore, 
injection of recombinant VEGF increased MDSC 
population in vivo, and liver-specific overexpression of 
VEGF led to accumulation of proangiogenic MDSCs in a 
SDF1α/CXCR4 pathway-dependent manner [27]. 
In line with these data, anti-VEGF treatment may 
have potential immune-modulatory functions. Sorafenib, 
the first therapy approved in advanced HCC stage, 
exerts its activity by a pan-VEGF receptor inhibition. 
Preclinical studies in liver cancer models showed that 
sorafenib decreases MDSC and T-reg levels in spleen, 
bone marrow and tumor, restraining their function as well 
[28]. Nevertheless, sorafenib seems to decrease IL-12 
expression and to impair DCs function [29]. At the same 
time, excessive pruning of tumor vasculature over time 
could aggravate hypoxia in the tumor microenviroment, 
resulting in high hypoxia-inducible factor-1α (HIF)-1α 
levels, which enhances immune checkpoint molecules 
expression such as PD-L1 in MDSCs and macrophages 
[30]. 
Chen et al. examined the effects of implementing 
anti-PD1 monoclonal antibody (mAb) to sorafenib in 
mice with HCC. The increased hypoxia after sorafenib 
resulted in increased intratumoral levels of PDL-1 
and up-regulation of SDF1α/CXCR-4 pathway with a 
consequent accumulation of immunosuppressive cells. 
Anti-PD-1 mAb administration did not significantly delay 
tumor growth when combined with sorafenib alone, even 
if the combination of an anti-PD-1 with sorafenib and 
AMD3100, an anti-CXCR-4 molecule, notably restrained 
tumor growth and metastasis [31]. 
According to these results, a potential future 
approach could be represented by a careful titration 
of VEGF inhibition with the aim to block the VEGF 
pathway and contemporarily alleviate hypoxia by vascular 
normalization, enhancing immunotherapy efficacy [32]. 
Trials evaluating a combined approach comprising anti-
angiogenesis drugs and immunotherapy are currently 
ongoing (Table 1). 
HCC IMMUNE-RESPONSE STRATEGIES
There are three main strategies to improve tumor-
specific immune response (Figure 2): i) adoptive 
immunotherapy - HCC-epitopes immunized cells, 
which recognize and act against cancer cells; ii) indirect 
immunological strategies - cytokines, immune checkpoint 
blockade mAbs, cancer vaccines used to increase immune 
system activity; iii) indirect non immunological strategies 
- antigen-encoding mRNA strategy in HCC, metronomic 
chemotherapy, oncolytic viruses [33]. Table 2 summarises 
the main clinical trials and restrospective studies or meta-
analysis in HCC immunotherapy.
Table 1: Combination of anti-angiogenetictherapy and immunotherapy clinical trials
Phase Anti-angiogenesis drug Immunecheckpoints  blocker Design Primary endpoint(s) Clinical trail ID
I
Angiokinase inhibitor 
targeting VEGFR 1-3, 
FGFR 1-3, and PDGFR Α/Β 
(nintedanib) 
IGG4 anti-PD-1 blocking 
mAb (pembrolizumab) 
Pembrolizumab + 
nintedanib (PEMBIB) 
in second line HCC 
Maximum tolerated 
dose and dose limiting 
toxicities
NCT02856425
I Anti-VEGFR2  antibody (ramucirumab) 
Anti–PD-L1 immune 
checkpoint inhibitor 
(MEDI4736) 
Ramucirumab 
+ MEDI4736 in 
metastatic or locally 
advanced and 
unresectable HCC
Dose limiting toxicities NCT02572687
I/II VEGFR2-TKI (apatinib) Anti-PD-1 mAb (SHR-1210)
Apatinib + 
SHR-1210 in advanced 
HCC
Overall survival rate NCT02942329
III VEGFR –TKI (sorafenib) Pexastimogene devacirepvec (Pexa-Vec) 
Sorafenib VS sorafenib 
+ Pexa-Vac in advanced 
HCC
Overall survival NCT02562755
Abbreviation – FGFR: fibroblast growth factor receptor; HCC: hepatocellular carcinoma; mAb: monoclonal antibody; 
PDGFR: platlet derived growth factor receptor; TKI: tyrosin kinase inhibitor; VEGFR: vascular endothelial growth factor 
receptor.
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ADOPTIVE IMMUNOTHERAPY
Adoptive immunotherapy utilizes NK and cytokine 
induced killer (CIK) cells for autologous cells reinfusion 
immunized with cancer epitopes. NK cells are immune 
lymphocytic cells resident in reticuloendothelial organs 
with a key role in immune and anti-tumor defense [34]. 
Thirty-seven HCC patients treated with 
radiofrequency ablation (RFA) showed a phenotypic 
and functional activation of autologous NK-cells [35]. 
Currently, adjuvant autologous NK cell reinfusion is being 
evaluated in 2 ongoing clinical studies in transplant and 
resected patients ( NCT01147380 [36] and NCT02008929 
[37]).
CIK cells are a heterogeneous cell population 
comprising CD3+ CD56+, CD3+ CD56− and CD3− 
CD56+ cells, which are able to both recognize tumor 
antigens and kill cancer cells directly [38]. Several 
studies reported an improved outcome, using CIK cells 
as adjuvant therapy after liver surgery in HCC patients. In 
Figure 1: Pathogenetic mechanisms of immune-tolerance in HCC. Abbreviation - CAF: cancer associated fibroblast; CTLA4: 
cytotoxic T-limphocite antigen-4; HBV: hepatits B virus; HCV: hepatits C virus; h-SC: hepatic stellate cells; IDO: indoleamine 2,3 
dioxygenase; IL: interleukin; LSEC: liver sinusoidal endothelial cells; MDSC: myeloid-derived suppressor cells; NK: natural killer; NKp30: 
natural killer protein 30; PD-1:programmed cell death protein 1; PD-L1: programmed cell death protein ligand 1; PG-E2: prostaglandin E2; 
TGF-β: transforming growth factor β; VEGF: vascular endothelial growth factor.
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particular, a phase II study evaluating the adjuvant role of 
CIK cells considered 127 HCC radically resected patients 
which were randomized into the following 3 arms: 3 or 
6 courses of adjuvant CIK cells infusion immunotherapy 
or observation only. Disease free survival (DFS) rate 
at 1, 3, and 5-year was 83.1%, 31.7%, and 23.3% in 3 
courses CIK cell infusion, 84.7%, 30.5%, and, 19.4% in 6 
courses CIK cell infusion, and 82.6%, 20.9%, and 11.2% 
in the control group, respectively. A statistically significant 
difference between 3 courses CIK cells (p = 0.001) and 6 
courses CIK cells (p = 0.004) as compared to the control 
group was observed in the absence of a statistically 
difference between CIK cell groups [39]. Similarly, a 
large retrospective study comparing surgery alone (206 
patients) with surgery followed by CIK cell transfusion 
(204 patients) showed a significantly better prognosis in 
the CIK group. The 1-, 2-, 3-, 4-, and 5-year OS rates of 
CIK group were higher than surgery alone group: 93.6%, 
83.3%, 76.6%, 71.1%, 65.9% and 84%, 69.2%, 61.6%, 
56.9%, 50.2%, respectively, with a significant difference 
between the two groups (log-rank test; p = 0.0007). 
Moreover, patients treated with more than 8 cycles of cell 
transfusion showed significantly better survival than those 
treated with less than 8 cycles (p = 0.0272). CIK group 
displayed significantly better OS than surgery-alone group 
in patients with more than 5-cm tumors (p = 0.0002) [40].
Another retrospective study compared 85 patients 
treated with adoptive autologous CIK cell transfusion 
in combination with transarterial chemoembolization 
(TACE) plus RFA, versus 89 patients treated with loco-
regional therapy alone. Despite similar response rates, 
the TACE+RFA+CIK cell group showed a significant 
improvement in terms of longer progression free survival 
(PFS) (17 months versus 10 months, p = 0.001) and OS 
(56 months versus 31 months, p = 0.001) compared to the 
TACE+RFA group [41]. Recently, in a multicenter phase 
III study, 230 HCC patients treated by surgery, RFA or 
percutaneous ethanol injection were randomized to receive 
adjuvant autologous CIK cells infusion or not, showing a 
median DFS of 44 months and 30 months, respectively (p 
= 0.010 by 1-sided log-rank test) [42]. A meta-analysis, 
including 13 phase II/III trials evaluating the use of the 
CIK cell adjuvant after RFA and TACE, demonstrated a 
significantly improved 1-year OS (OR = 0.25, 95% CI: 
0.12 to 0.52, p < 0.001) and 2-year OS (OR = 0.17, 95% 
CI: 0.07 to 0.43, p < 0.001) [43]. Finally, a systematic 
Figure 2: The three main strategies of HCC immunotherapy
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Table 2: Clinical trials and retrospective studies or meta-analysis in immunotherapy treatments of HCC
Immune-therapy 
strategies Trial/study Design Results Ref.
Adoptive immunotherapy
Randomized phase 
II 
Adjuvant 6 versus 3 courses of 
CIK cell infusion immunotherapy 
in resected patients
1-, 3-, 5-y - DFS rates 
6 courses CIK infusion: 84.7%, 30.5%, 19.4% 
3 courses CIK infusion: 83.1%, 31.7%, 23.3% 
39
Retrospective 
analysis 
Adjuvant CIK cell infusion 
immunotherapy in resected 
patients
1, 2, 3, 4, 5-y OS rates 
Untreated group: 84%, 69.2%, 61.6%, 56.9%, 
50.2 % 
CIK cells group: 93.6%, 83.3%, 76.6%, 
71.1%, 65.9%
40
Retrospective 
analysis
Adjuvant autologous CIK cell 
infusion immunotherapy versus 
control after locoregional 
procedures 
Overall RRs: 79.8% versus 76.5% 
OS: 56 months versus 31 months
PFS: 17 months versus 10 months
41
Phase III 
Adjuvant activated CIK cells 
infusion immunotherapy versus 
control in resected patients or 
after RFA or after percutaneous 
ethanol injection
mDFS: 44 months versus 30 months 42
Meta-analysis 
including 13 phase 
II/III trials 
Adjuvant activated CIK cells 
infusion immunotherapy after 
RFA and/or TACE
1-y OS - OR=0.25 (95% CI, p < 0.001)
2-y OS - OR=0.17 (95% CI, p < 0.001) 43
Indirect immunological 
strategies
Randomized phase 
II
TACE plus IFN-α versus TACE in 
unresectable HCC
mOS: 29 months versus 26 months 
(p = 0.003)
mDFS: 23.6 months versus 20.3 months 
(p = 0.027)
51
Phase II 
Combined intrarterial 5-FU plus 
PEG-IFN α-2b in advanced HCC 
with portal venous invasion
ORR: 73%
mOS: 29.9 months 52
Meta-analysis of 
10 trials Adjuvant IFN versus placebo
Recurrence rate - OR: 0.42 (CI 95%; p < 
0.00001) 53
Phase I Tremelimumab in advanced HCC
Good toxicity profile
PR: 17.6%
SD: 45%
58
Phase I/II Nivolumab in advanced HCC
Good toxicity profile
ORR: 20%
Median duration of response: 9.9 months
62
Phase I 
Pulsed DCs by autologous cells 
from tumor lysate in advanced 
HCC
Positive feasibility
Low toxicity profile 70
Phase II DCs pulsed with HepG2 cell lysate in advanced HCC
DCR:28%
Low toxicity profile 71
Phase I AFP-derived vaccine in advanced HCC T-cell increased activity in all patients 74
Phase I GPC3 vaccine advanced HCC
mOS: 12.2 months in high T-cell expressing 
patients
mOS: 8.5 months in low expressing patients
75
Phase II Telomerase peptide GV1001 vaccine in advanced HCC
Low toxicity profile
6 mo SD: 45.9%
mTTP: 57 days
78
Phase II Second line therapy with lenalidomide 
OS: 7.6 months 
PR: 15%
Indirect non 
immunological strategies 
Phase II
Metronomic capecitabine  in 
previously untreated and resistant 
to/intolerant of sorafenib 
advanced  HCC 
mPFS (untreated): 6 months 
mPFS (second line): 14.4 months 89
Randomized phase 
II 
Two doses of JX-594 (high 
versus low dose) vaccinia virus in 
advanced HCC 
Positive feasibility
mOS: 14.1 versus 6.7 months 90
Abbreviation - CI: confidence interval; CIK: cytokine induced killer; DC: dendritic cell; DCR: disease control rate; DFS: 
disease free survival; HCC: hepatocellular carcinoma; IFN: interferon; mDFS: median disease free survival; mOS: median 
overall survival; mTTP: median time to progression; ORR: overall response rate; OS: overall survival; PFS: progression free 
survival; PR: partial response; RFA: radiofrequency ablation; RR: recurrence rate; SD: stable disease; TACE: transarterial 
chemoembolization.
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review of the literature, including 14 eligible articles, 
confirmed that CIK cells could prevent recurrence in 
resected HCC [44]. Currently, several phase III/IV studies 
are ongoing on autologous CIK cell infusion adjuvant 
therapy. NCT01749865 [45] and NCT00769106 [46] are 
two phase III studies which will assess time to recurrence 
after surgery as the primary end-point in HCC patients 
who underwent to radical resection.
In conclusion, the adoptive immunotherapy 
achieved favorable results in particular in the adjuvant 
setting leading to these last phase III trials in HCC.
INDIRECT IMMUNOLOGICAL 
STRATEGIES
Interferons
Recombinant human IFN-α was the first 
immunotherapy to undergo substantial clinical 
development in HCC, due to the extensive experience 
gained in the treatment of chronic viral hepatitis as 
well as to its anti-angiogenic and immunostimolatory 
proprieties [47]. In vitro studies showed a pro-apoptotic 
effect of IFN-α, IFN-β, and IFN-γ on HCC cells [48-
50]. A phase II randomized trial comparing TACE plus 
IFN-α versus TACE in unresectable HCC showed median 
DFS of 23.6 months and 20.3 months in TACE-IFN-α 
and TACE groups, respectively (p = 0.002). mOS of 29 
months and 26 months were observed in the TACE-IFN-α 
and control group, respectively (p = 0.003) [51]. A phase 
II trial evaluating the efficacy of combined intrarterial 
5-fluorouracil (5-FU) and systemic pegylated IFN α-2b in 
patients with advanced HCC with portal venous invasion 
reported mOS of 29.9 months [52]. A meta-analysis of 
10 trials (8 randomized and 2 non-randomized controlled 
studies) demonstrated that recurrence rate (RR) was 
significantly lower in patients treated with adjuvant IFN 
with respect to the placebo group (OR = 0.66; 95% CI 
= 0.50 to 0.86; p = 0.02). Death rates were significantly 
decreased (OR = 0.42; 95% CI = 0.32 to 0.56; p < 
0.00001) and subgroup analysis showed an advantage for 
the group treated with TACE (OR = 0.33; 95% CI = 0.21 
to 0.50; p < 0.00001) compared to patients treated with 
surgery (OR = 0.51; 95% CI = 0.36 to 0.72; p = 0.0002) 
[53]. An in vivo study demonstrated that sorafenib in 
combination with IFN synergistically suppressed tumor 
growth, inducing apoptosis [54]. An ongoing, phase II 
randomized trial is comparing IFN-α plushepatic arterial 
infusion 5-FU versus cisplatin plus 5-FU in HCC patients 
after liver resection (NCT01834963) [55].
Immune checkpoint inhibitors
Several negative immunologic regulator targets 
revolutionized cancer care in melanoma, renal cancer, and 
non small cell lung cancer with significant improvement in 
terms of mOS and response rate [56]. CTLA-4 and PD-1 
are the most studied immune checkpoint inhibitors in HCC 
[57]. 
Tremelimumab, an anti-CTLA-4 mAb, has been 
tested in a phase I trial recruiting 21 advanced HCC 
patients. This molecule was well tolerated with 17.6% 
and 58.8% of partial response (PR) and stable disease , 
respectively. Interestingly, an over 200-fold decrease of 
serum viral load in 12 HCC HCV infected patients treated 
with tremelimumab has been seen [58]. A phase I trial of 
tremelimumab in combination with RFA or TACE has 
been concluded (NCT01853618) [59]. This combined 
therapy proved to be safe and of the 10 patients evaluable 
for response outside loco-regional treatments, all showed 
immune cell infiltration and 4 achieved confirmed PR [60]. 
Nivolumab, a fully human mAb anti-PD-1 has been 
tested in advanced HCC patients in the CheckMate 040 
study. It presented a fairly good toxicity profile with a 
20% of response rate in 214 patients treated in the dose 
expansion phase. Median duration of response was 
9.9 months with a disease control rate (DCR) of 64%. 
Moreover, 9-months OS rate in the expansion phase was 
74% (95% CI 67-79) [61]. 
Preliminary studies evaluating the role of 
MEDI4736, an anti PD-L1 mAb, suggested a favoreable 
toxicity profile with a DCR at 12 weeks of 21% [62]. 
The study protocols of two clinical trials involving 
the anti-PD-1 mAb pembrolizumab have been recently 
presented at ASCO 2017 Gastrointestinal Cancers 
Symposium. The former is a single-arm, multicentric, 
phase 2 study (KEYNOTE-224) designed to evaluate the 
efficacy and safety of pembrolizumab in previously treated 
advanced HCC patients. [63]. The latter is a double-blind, 
placebo-controlled phase 3 study (KEYNOTE-240) 
which will randomize pembrolizumab versus placebo in 
previously treated advanced HCC [64].
In a murine melanoma vaccine model, inhibition of 
both CTLA-4 or PD-1 increased the proportion of CTLA-
4 and PD-1-expressing CD4/CD8 tumor infiltrating T 
effector cells and decreased intratumoral T regulatory 
cells, as compared to either agent alone [65]. Given the 
increased efficacy observed with combination approaches 
in other tumor types, the Checkmate 040 trial will evaluate 
the efficacy and toxicity of the combination of ipilimumab 
plus nivolumab (NCT01658878) [66]. 
Currently, several anti-immunocheckpoint inhibitor 
mAbs are being developed (Table 3). These drugs are 
radically changing the approach to oncological diseases, 
being able to offer both a longer duration of response and a 
better toxicity profile compared to chemotherapy or target 
therapy. Nevertheless, the economic impact of these drugs 
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will force clinicians and researchers to select patients who 
should be elegible for these treatments. In this scenario, 
the identification of biomarkers able to predict the 
response to checkpoint blockades represents an intriguing 
area of research. Immunohistochemical evaluation of PD-
L1 is a tested predictive biomarker for the response to 
PD-1/PD-L1 mAbs. Indeed, the histological detection of 
tumor infiltration of immune cells or their molecules in 
the tumor microenvironment may be indirect predictive 
biomarkers of response to PD-1/PD-L1 checkpoint 
blockades. Moreover, mismatch-repair deficiency gene 
analysis should improve the clinical benefit of immune 
checkpoint inhibitors [67].
Vaccine strategy
The aim of cancer vaccination is the induction and 
continuance of a tumor-specific immune response by 
eliciting effector T cells that can specifically decrease 
tumor load and control tumor relapse. Various approaches 
have been used in this setting: i) pulsed DCs , ii) peptide-
based vaccines, and iii) DNA-based vaccines.
DCs play a key role in both innate and adaptive 
immunity. They resulted increased in peripheral blood 
and lymph nodes of HCC patients [68]. Moreover, DC 
infiltration in HCC lesions has been associated with 
a better prognosis in resected patients [69]. A phase I 
trial showed a feasible and well tolerated anti-cancer 
immunization through the stimulation of DCs by 
autologous cells from HCC lysate [70]. A phase II trial 
with DCs pulsed with HepG2 cell lysate demonstrated a 
DCR of 28 % in the absence of relevant adverse events 
in 39 advanced HCC patients [71]. Finally, in 20 and 13 
HCC patients treated with TACE and TACE followed by 
DC infusion, respectively, a more effective enhancement 
of tumor specific immune response with the combination 
approach was observed, without differences in terms 
of RR [72]. An ongoing phase I trial is evaluating the 
administration of intra-tumoral DC allogenic vaccine 
(NCT01974661) [73]. The external passive immunization 
of these patients with reinfusion of DCs able to develop an 
immune response against tumor cells could be a feasible 
and active strategy even if the complexity of the process 
may represent a key challenge.
Table 3: Clinical trials of immune-checkpoint  blocker in HCC patients
Immune-
checkpoints 
target
Drug Associated treatment Phase Status Results Clinical trial ID
CTL-A4
Tremelimumab None II Completed PR: 17.6%; SD: 58.8% NCT01008358
Tremelimumab TACE or ablation I Recruiting
mPFS for study 
population (n = 17): 
7.4 months 
NCT01853618
PD-L1/CTL-A4
Durvalumab/
Tremelimumab TACE or RFA I/II Recruiting NA NCT02821754
Nivolumab/Ipilimumab None I/II Recruiting NA NCT01658878
PD-1
Nivolumab
TGFBR1 
kinase inhibitor 
(galunisertib)
I/II Recruiting NA NCT02423343
Nivolumab None I/II Recruiting
Good toxicity profile; 
response rate: 20%; 
median duration of 
response: 9.9 months 
CA209-040
Anti-PD-1 antibody 
(not specified) Decitabine I/II Recruiting NA NCT02961101
Pembrolizumab None II Recruiting NA NCT02702414
PDR001 c-met inhibitor (INC280) II Recruiting NA NCT02795429
PDR001 Anti-TGF beta antibody (NIS793) II
Not yet 
recruting NA NCT02947165
Abbreviation– CR: complete response; CTLA4: receptor and cytotoxic T-limphocite antigen-4; RFA: radiofrequency ablation; 
PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand1; PR: partial response; SD: stable disease; 
TACE: transarterial chemoembolization.
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αFP and glypican-3 (GPC3) are the main HCC 
tumor associated antigens of peptide-based vaccine. 
αFP-derived vaccine has been evaluated in a phase I trial 
reporting a T-cell increased specific activity in all patients 
[74]. Another phase I trial involving 33 advanced HCC 
patients treated with GPC3 vaccine reported a mOS of 
12.2 months (95% CI = 6.5-18.0) and 8.5 months (95% 
CI = 3.7-13.1) (p = 0.033) in patients with a high GPC3-
related CTLs expressionand in those with a low GPC3-
related CTL expression, respectively [75].
Recently, a promising ongoing phase II trial (UMIN-
CTR: 000002614) is evaluating GPC3 vaccine after 
surgery or RFA [76]. Currently, preclinical data for GPG3 
DNA-based vaccines indicated the induction of specific 
and effective cellular antitumor immunity against GPC3 
only in in vivo models [77]. No clinical trials are ongoing 
even if a report of two pretreated αFP positive HCC 
patients treated with αFP-DNA vaccine and adenovirus 
driven immunization showed promising safety and 
immunogenic T cell response [78]. Although it was not a 
characteristic antigen, the telomerase peptide GV1001 was 
evaluated in a clinical phase II trial with a median TTP 
of 57 days [79]. Another therapeutic strategy potentially 
able to improvethe clinical outcome of these patients could 
be the combination of vaccination with anti-angiogenic 
tyrosine-kinase inhibitors (TKIs), such as sorafenib [80]. 
Regarding this, an ongoing phase III trial is comparing 
vaccinia virus based immunotherapy plus sorafenib versus 
sorafenib alone (PHOCUS) (NCT02562755) [81]. 
Vaccines have been the first therapeutic strategy 
in immuno-oncology. Anyway, after decades of studies, 
despite the fact that some positive data are available 
in literature, there are no phase III trials to prompt this 
approach in HCC.
Immunomodulator strategy
Initial data regarding the activity of 
immunomodulators in HCC treatment are currently 
avaiable. Lenalidomide has been evaluated in a phase II 
study after sorafenib failure or intolerance, with PR of 
15% and 7.6 months of mOS [82]. In an orthotopic HCC 
model, lenalidomide plus sorafenib showed an interesting 
tumor growth inhibition, with a significant increase of T 
cytotoxic IFN-γ infiltrating tumor cells [83]. Further data 
are mandatory in this therapeutic setting.
INDIRECT NON IMMUNOLOGICAL 
STRATEGIES
Antigen-encoding mRNA strategy
Another recent vaccination strategy is represented 
by the antigen-encoding mRNA technique. mRNA 
encodes genetic information corresponding to whole 
antigens, with a consequent antigen expression and 
presentation. This approach is not associated to the risk of 
genomic integration, with a more favorable safety profile 
compared to the use of DNA sequences. On one hand, DCs 
can be cultivated and electroporated with mRNA followed 
by their restitution into the patient. On the other, “nude 
mRNA” can be injected intratumorally. In both cases anti-
tumour immune responses were achieved in a variety of 
mouse models [84,85]. Lastly, a recent study is evaluating 
the role of TriMix mRNA and mRNA encoding the target 
antigens GPC3 and MAGE-C2 mRNA when injected 
intranodally the same day as the RFA treatment [86].
Metronomic chemotherapy
Metronomic chemotherapy is the admnistration of 
low-dose chemoterapeutic drug for a long period in the 
absence of drug-freebreaks [87].
Several Authors demonstrated that tumor response 
to this therapeutic approach is related not only to a 
direct antineoplastic activity but also to the following 
immune-stimulatory: i) activation of immunity, ii) 
induction of tumor dormancy, and iii) chemotherapy-
driven dependency of cancer cells [88]. An Italian, phase 
II non-randomized trial included 59 previously untreated 
patients with advanced HCC and 31 patients resistant to or 
intolerant of sorafenib treated with capecitabine 500 mg 
twice daily until progression of disease or unacceptable 
toxicity. [89]. Authors reported mPFS of 6 months and 
14.4 months in the two cohorts, respectively. Treatment 
was well tolerated with an acceptable toxicity. Anyway, no 
immunological analyses have been performed in this trial.
Oncolytic viruses
Oncolytic viruses have a dual mechanism of 
action. In fact, they are able to induce both tumor cells 
lysis during viral replication and unmasking of tumor 
antigens for cell-mediated activation. A randomized 
phase II trial tested the feasibility of two doses of JX-594 
(Pexa-Vec), an oncolytic and immunotherapeutic vaccinia 
virus in 30 HCC patients. Treatment was well tolerated 
with flu-like symptoms, anorexia, lymphopenia, and 
hypertransaminasemia, and a significantly longer mOS in 
high-dose arm respect to low-dose arm (14.1 months and 
6.7 months, respectively) [90]. On the contrary, JX-594 
did not extended mOS with respect to best supportive care 
in second line therapy after sorafenib [91]. Currently, a 
phase III study is randomizing the administration of this 
virus followed by sorafenib versus sorafenib alone in 
advanced HCC untreated patients (NCT02562755) [81]. 
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CONCLUSIONS
Today, sorafenib and regorafenib are the only 
therapies that have shown efficacy in advanced HCC. 
New molecular approaches have been experimented, 
without significant improvement of survival. Therefore, 
we urgently need to identify new therapeutic strategies 
as well as to select patients suitable for these treatments. 
Immunotherapy is laying the foundations for solid 
treatments. In recent years different clinical studies 
examining the role of immunotherapy to treat HCC 
have been conducted with initial promising results in 
particular regarding CIK cells in the adjuvant setting 
and immune checkpoint inhibitors in advanced stages. 
The results of the several ongoing trials are warranted. 
Furthermore, since the hepatic immune system plays an 
important role in reduction ofthe immune response, the 
possibility of unmasking these mechanisms seems to be a 
winning weapon in HCC, with immunotherapy playing a 
fundamental role in this cancer in the near future.
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